Mineralys Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
Mineralys Therapeutics, Inc. carries a market capitalization of 1.85B, placing it among publicly traded companies globally.
| Market Cap | 1.85B |
| Enterprise Value | N/A |
Share Statistics
Mineralys Therapeutics, Inc. currently has 88.35M shares outstanding.
| Shares Outstanding | 88.35M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 4.33 |
| P/TBV Ratio | 4.33 |
| P/FCF Ratio | -15.49 |
| P/OCF Ratio | -15.49 |
Financial Position
Mineralys Therapeutics, Inc. maintains a current ratio of 34.46, meaning it holds 34.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 34.46 |
| Quick Ratio | 34.24 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -80.88 |
| Return on Assets (ROA) | -69.67 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Mineralys Therapeutics, Inc.'s stock has declined approximately -52.62681% over the past 52 weeks. The 50-day moving average sits at 25.81, while the 200-day moving average is 27.60.
| Beta (5Y) | N/A |
| 52-Week Price Change | -52.62681% |
| 50-Day Moving Average | 25.81 |
| 200-Day Moving Average | 27.60 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -370.75M, while operating income came in at -370.79M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -370.79M |
| Pretax Income | -349.58M |
| Net Income | -349.58M |
| EBITDA | -370.75M |
| EBIT | -370.79M |
| Earnings Per Share (EPS) | -4.39 |
Balance Sheet
Total book value stands at 550.92M, with working capital of 646.48M providing operational flexibility.
| Cash & Cash Equivalents | 661.41M |
| Total Debt | N/A |
| Net Debt | -138.27M |
| Equity (Book Value) | 550.92M |
| Book Value Per Share | 6.24 |
| Working Capital | 646.48M |
Cash Flow
Mineralys Therapeutics, Inc. produced -138.79M in operating cash flow over the past twelve months. After subtracting -15,000.00 in capital expenditures, free cash flow totaled -138.80M - equivalent to -1.74 per share.
| Operating Cash Flow | -138.79M |
| Capital Expenditures | -15,000.00 |
| Free Cash Flow | -138.80M |
| FCF Per Share | -1.74 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -27.66 |
| FCF Yield | -6.46 |
Scores
Mineralys Therapeutics, Inc. posts an Altman Z-Score of 10.01, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 10.01 |